Abstract Library

#4459 Sequential alkylating therapy and pembrolizumab induce near-complete response in high tumour mutational burden pancreatic neuroendocrine tumour: A case report

Introduction: Traditional treatment for neuroendocrine tumours (NETs), including surgery, somatostatin therapy, and targeted therapy, often fails in advanced disease. Alkylating therapy can increase tumour mutational burden (TMB), and the recent KEYNOTE-158 study approved pembrolizumab for advanced solid tumours with a high TMB.

Conference:

Presenting Author:

Authors: Paranjpe I, Hornbacker K, Vadde S, Fisher G, Shaheen S,

Keywords: pancreatic neuroendocrine tumour, immunotherapy, pembrolizumab, tumour mutational burden, TMB,

#3871 A phase 2, randomized, parallel-group study to evaluate the safety, pharmacokinetics, and dose response of paltusotine treatment in patients with carcinoid syndrome

Introduction: While long-acting somatostatin receptor ligands (SRLs) are mainstay treatments for carcinoid syndrome (CS), symptom relief at labelled doses is inadequate for many patients. Paltusotine is a novel oral, nonpeptide, selective somatostatin receptor type 2 agonist. In patients with acromegaly, paltusotine maintains plasma IGF-1 levels in patients switching from long-acting SRLs. Paltusotine was well tolerated in phase 2 acromegaly studies.

Conference:

Presenting Author:

Authors: Chauhan A, Shaheen S, Usiskin K, Odueyungbo A, Mui C,

Keywords: Paltusotine, Phase 2 trial, Somatostatin receptor agonist, Safety, Pharmacokinetics, Carcinoid syndrome,

#3589 Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET)

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is a targeted radionuclide treatment for patients with neuroendocrine tumors (NET).

Conference:

Presenting Author: Duan H

Authors: Duan H, Song H, Ferri V, Fisher G, Shaheen S,

Keywords: PRRT, NET, Dotatate, PET, early response, Pseudo-progression,

#3248 A single institution experience with peptide receptor radionuclide therapy (PRRT) in advanced pheochromocytoma and paraganglioma

Introduction: Pheochromocytomas and parangliomas (PPGLs) are very rare tumors. Due to their heterogenicity, there is a lack of treatment guidelines, and therapy options generally are very limited.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Duan H

Authors: Duan H, Ferri V, Fisher G, Shaheen S, Davidzon G,

Keywords: paraganglioma, pheochromocytoma, PRRT, 177Lu-Dotatate,

#3245 A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)

Introduction: The NETTER-1 trial showed that patients with midgut neuroendocrine tumors (NETs) had longer progression-free survival (PFS) when treated with peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in combination with octreotide LAR vs octreotide LAR alone.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Duan H

Authors: Duan H, Ferri V, Fisher G, Shaheen S, Davidzon G,

Keywords: non-midgut NET, NET, PRRT, 177Lu-Dotatate,